Genmab A/S (NASDAQ:GMAB) Rating Lowered to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Genmab A/S (NASDAQ:GMAB - Free Report) from a buy rating to a hold rating in a report published on Saturday.

Several other equities analysts have also weighed in on GMAB. Truist Financial cut their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB traded down $0.83 during mid-day trading on Friday, reaching $22.03. The company had a trading volume of 1,569,265 shares, compared to its average volume of 1,177,614. The stock has a fifty day moving average of $20.72 and a two-hundred day moving average of $20.75. The company has a market capitalization of $14.13 billion, a price-to-earnings ratio of 12.52, a PEG ratio of 7.54 and a beta of 0.96. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. Sell-side analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in shares of Genmab A/S in the fourth quarter valued at about $2,463,000. AIMZ Investment Advisors LLC bought a new position in shares of Genmab A/S in the fourth quarter valued at about $3,525,000. Northern Trust Corp raised its holdings in shares of Genmab A/S by 18.8% in the fourth quarter. Northern Trust Corp now owns 599,381 shares of the company's stock valued at $12,509,000 after buying an additional 94,858 shares during the last quarter. Sei Investments Co. raised its holdings in shares of Genmab A/S by 55.2% in the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company's stock valued at $1,205,000 after buying an additional 20,525 shares during the last quarter. Finally, LPL Financial LLC raised its holdings in shares of Genmab A/S by 3.3% in the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock valued at $4,079,000 after buying an additional 6,288 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.